Evoq Remedies Ltd
Incorporated in 2010, EVOQ Remedies
Ltd is engaged in the trading of pharmaceuticals formulation and allied products[1]
- Market Cap ₹ 9.14 Cr.
- Current Price ₹ 3.67
- High / Low ₹ 9.50 / 2.11
- Stock P/E 102
- Book Value ₹ 17.9
- Dividend Yield 0.00 %
- ROCE 0.35 %
- ROE 0.26 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.21 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 5.33% over past five years.
- Promoter holding is low: 11.2%
- Company has a low return on equity of 2.57% over last 3 years.
- Contingent liabilities of Rs.6.55 Cr.
- Company has high debtors of 268 days.
- Promoter holding has decreased over last 3 years: -62.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | |
3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 | |
Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 |
OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% |
0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | 2.41 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 |
Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 |
Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | |
0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | |
EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | -11% |
TTM: | 190% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -56% |
TTM: | -80% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -45% |
1 Year: | -59% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 3% |
Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 |
Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 |
0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 | |
2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 | |
Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | |
Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 |
Cash Flows
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
0.01 | -0.02 | 0.03 | -26.43 | -4.35 | 5.32 | -14.62 | |
0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.26 | |
0.00 | 0.00 | 0.00 | 29.49 | 1.42 | -5.34 | 14.97 | |
Net Cash Flow | 0.01 | -0.02 | 0.03 | 3.06 | -2.94 | -0.03 | 0.09 |
Ratios
Figures in Rs. Crores
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 | 267.54 |
Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 | 61.90 |
Days Payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 | 97.59 |
Cash Conversion Cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 | 231.85 |
Working Capital Days | 1.12 | 1.21 | 26.23 | 436.56 | 440.90 | 2,263.00 | 1,369.06 |
ROCE % | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% |
Documents
Announcements
- Intimation Regarding Book Closure 26 Aug
- Reg. 34 (1) Annual Report. 26 Aug
- Intimation Of The Annual General Meeting To Be Held On 17Th September, 2025 26 Aug
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
26 Aug - Recommend H Thakkar & Co. as statutory auditor (FY2025-26–2029-30); AGM on 17 Sep 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting And Intimation As Per Regulation 30 Of SEBI (LODR) Regulation, 2015
26 Aug - Recommend M/s H Thakkar & Co. LLP as statutory auditor FY2025-26 to FY2029-30; AGM 17 Sep 2025.
Business Overview:[1][2]
Company is in the business of marketing, trading, and distribution of a wide range of pharmaceutical formulation products. Apart from this, the company also deals in trading of active pharmaceutical ingredients, Nutraceutical, Ayurvedic, and Herbal Products